KIF18A-IN-2 is a potent KIF18A inhibitor ( IC 50 =28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer In Vivo KIF18A-IN-2 (compound 23) (100 mg/kg; i.p., single) exhibits a significant and sustained pharmacodynamic response, increasing the number of mitotic cells (pH3 positive cells) in tumor tissues for up to 24 hours . Pharmacokinetic Parameters of KIF18A-IN-2 in female CD-1 mice . IP (100 mg/kg) C max (μM) 12.6 AUC 0-24 (μM·h) 147 C 24h (μM) 2.9 PPB (f u ) 0.007 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female athymic nude mice (4-7 weeks; injected with human OVCAR-3 HGSOC cells) Dosage: 100 mg/kg Administration: i.p., single Result: Showed a significant and sustained pharmacodynamic response, increasing the number of mitotic cells (pH3 positive cells) in tumor tissues for up to 24 hours. Form:Solid IC50& Target:IC 50 : 28 nM (KIF18A)